

Kurt A Jaeckle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6141242/publications.pdf>

Version: 2024-02-01

33
papers

3,857
citations

304743

22
h-index

414414

32
g-index

35
all docs

35
docs citations

35
times ranked

3653
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 1999, 17, 2572-2572.	1.6	850
2	Phase II Trial of Temozolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	1.6	688
3	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. <i>Journal of Clinical Oncology</i> , 1999, 17, 3110-3116.	1.6	393
4	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study ¹ . <i>Neuro-Oncology</i> , 2006, 8, 189-193.	1.2	200
5	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017, 19, now183.	1.2	157
6	Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 2305-2311.	1.6	151
7	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014, 16, 1176-1185.	1.2	141
8	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. <i>Neuro-Oncology</i> , 2015, 17, 1261-1269.	1.2	126
9	Neurological Manifestations of Neoplastic and Radiation-Induced Plexopathies. <i>Seminars in Neurology</i> , 2004, 24, 385-393.	1.4	109
10	An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. <i>Journal of Neuro-Oncology</i> , 2002, 57, 231-239.	2.9	102
11	Neurologic Manifestations of Neoplastic and Radiation-Induced Plexopathies. <i>Seminars in Neurology</i> , 2010, 30, 254-262.	1.4	98
12	Phase I Clinical Trial of Intrathecal Topotecan in Patients With Neoplastic Meningitis. <i>Journal of Clinical Oncology</i> , 2003, 21, 143-147.	1.6	93
13	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	1.2	93
14	Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. <i>Neurology</i> , 2009, 73, 1207-1213.	1.1	87
15	Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival. <i>Oncology</i> , 2003, 65, 259-266.	1.9	72
16	Neoplastic Meningitis From Systemic Malignancies: Diagnosis, Prognosis and Treatment. <i>Seminars in Oncology</i> , 2006, 33, 312-323.	2.2	70
17	Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response. <i>Journal of Clinical Oncology</i> , 2006, 24, 1246-1252.	1.6	65
18	Intrathecal Mafosfamide: A Preclinical Pharmacology and Phase I Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 1555-1563.	1.6	62

#	ARTICLE	IF	CITATIONS
19	CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021, 23, 457-467.	1.2	58
20	Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. <i>Journal of Neuro-Oncology</i> , 2006, 80, 83-90.	2.9	53
21	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	1.2	38
22	Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. <i>Journal of Neuro-Oncology</i> , 2009, 92, 165-175.	2.9	30
23	Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas. <i>Neurosurgery</i> , 1996, 39, 921-926.	1.1	23
24	Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. <i>Cancer Medicine</i> , 2020, 9, 7935-7942.	2.8	19
25	Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN exposure. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1303-1312.	2.0	18
26	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
27	Oligodendroglial Tumors. <i>Seminars in Oncology</i> , 2014, 41, 468-477.	2.2	11
28	Autoimmunity in paraneoplastic neurological syndromes: Closer to the truth?. <i>Annals of Neurology</i> , 1999, 45, 143-145.	5.3	8
29	Phase II NCCTG trial of RT+Irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. <i>Journal of Neuro-Oncology</i> , 2010, 99, 73-80.	2.9	8
30	Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). <i>Journal of Neuro-Oncology</i> , 2019, 143, 573-581.	2.9	7
31	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 95-111.	2.2	6
32	Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology. <i>Neuro-Oncology Practice</i> , 2019, 6, 283-288.	1.6	1
33	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2026-2026.	1.6	0